TrialESMO open2020

BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer.

Daisuke Kotani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.